Revolution Medicines, Inc.

Revolution Medicines Q2 FY26 — Daraxonrasib NDA Accepted, Strong Pipeline Progress in Pancreatic and Lung Cancers

Revolution Medicines Q1 FY26 — Daraxonrasib Shows Unprecedented OS Benefit in Pancreatic Cancer

Revolution Medicines Q4 FY25 — Pipeline Advancement and Commercialization Readiness

Revolution Medicines Q3 FY25 — Daraxonrasib Pancreatic Cancer Progress & Pipeline Expansion

Revolution Medicines Q2 FY25 — Pipeline Progress and Bolstered Financial Position

Revolution Medicines Q1 FY25 — Strong Clinical Progress in RAS(ON) Inhibitors and Pancreatic/NSCLC Expansion

Revolution Medicines Q4 FY24 — Advancing RAS(ON) Inhibitor Pipeline with Multiple Pivotal Trials